Clinical Trial Update: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating endocrine therapy with or without the PI3K inhibitor Inavolisib in HER2-positive, HR-positive, PIK3CA-mutant early breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inavolisib (Inavolisib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING